边缘vnp最新版
SGLT-2 inhibitor Farxiga shows impressive results from its latest clinical trial: it slows the loss of kidney function and reduces the risk of death in people with chronic kidney disease, with or without type 2 diabetes Continue Reading
If you have any questions or comments, please don't hesitate to contact us at comments@diaTribe.org.
If you know somebody who is affected by diabetes and who might benefit from the information diaTribe provides, tell them about us through Facebook, Twitter, or email.
SGLT-2 inhibitor Farxiga shows impressive results from its latest clinical trial: it slows the loss of kidney function and reduces the risk of death in people with chronic kidney disease, with or without type 2 diabetes Continue Reading